Newsroom

加州聖卡洛斯--(BUSINESS WIRE)--(美國商業資訊)-- 全球性腫瘤公司BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235)今日公布了HERIZON-GEA-01第三期試驗計畫內的第二次期中分析(IA2)及最終正式分析的最新生存結果，進一步證實TEVIMBRA® (tislelizumab)聯合ZIIHERA® (zanidatamab)及化療做為HER2陽性局部晚期或移轉性胃食管腺癌(GEA)病患一線治療的獲益。這些結果將於今日在西班牙馬德里舉行的2026年歐洲腫瘤內科學會(ESMO)大會的快速口頭報告環節以最新突破性摘要形式公布(LBA79)。 BeOne實質腫瘤醫療長Mark Lanasa, M.D.博士表示： 「繼今年8月獲得美國核准後，這些更長期的數據進一步證實TEVIMBRA聯合ZIIHERA及化療可做為所有一線HER2陽性晚期胃食管腺癌病患的新基準治療方案，無論PD-L1狀態如何。相較於trastuzumab聯合化療，TEVIMBRA聯合ZIIHERA及化療此前所展現的生存獲益幅度在更長隨訪...

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced updated results from the Phase 1 study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in patients with advanced clear cell renal cell carcinoma (ccRCC). The results were presented by Sumanta Pal, M.D., FASCO, professor and vice chair of academic affairs at City of Hope Comp...

BOSTON & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Frontier Medicines Corporation, a clinical-stage precision medicines company unlocking the proteome to develop small molecule oncology and immunology drugs against previously undruggable disease-causing targets, today announced promising preliminary clinical data from the ongoing Phase 1 monotherapy portion of its Phase 1/2 PROSPER trial evaluating FMC-376, a KRAS G12C ON+OFF inhibitor, in patients with advanced KRAS G12C-mutant solid tumor...

SAN FRANCISCO--(BUSINESS WIRE)--Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus...

سان كارلوس، كاليفورنيا--(BUSINESS WIRE)--اليوم، أعلنت BeOne Medicines Ltd.‎ (رمزها في Nasdaq:‎ ‏ONC‏; وفي HKEX: ‏06160؛ وفي SSE: ‏688235) وهي شركة عالمية متخصصة في علم الأورام، عن بيانات جديدة من العديد من الأدوية التجريبية المتميزة عبر مجالات أمراض الأورام الصلبة ذات الأولوية في European Society for Medical Oncology 2026 (مؤتمر الجمعية الأوروبية لعلم الأورام الطبي) ‎(ESMO)‎ (في الفترة 23-27 أكتوبر، مدريد). وتشمل العروض التقديمية سرطانات الجهاز الهضمي والرئة والثدي، وتعكس الزخم المتزايد لقطاع عل...

SAN CARLOS, Kalifornien--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), ein globales Onkologieunternehmen, gab heute auf dem Kongress 2026 der European Society for Medical Oncology (ESMO) (23.–27. Oktober, Madrid) neue Daten zu mehreren differenzierten Prüfpräparaten in seinen prioritären Krankheitsbereichen bei soliden Tumoren bekannt. Die Präsentationen umfassen gastrointestinale Krebserkrankungen, Lungen- sowie Brustkrebs und spiegeln die zunehmende Dynamik de...

SAN CARLOS, Califórnia--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), empresa multinacional de oncologia, anunciou hoje novos dados de múltiplos medicamentos experimentais diferenciados em suas áreas prioritárias de doenças tumorais sólidas no Congresso da Sociedade Europeia de Oncologia Médica (ESMO) de 2026 (23 a 27 de outubro em Madri). As apresentações abrangem tipos de câncer gastrointestinais, de pulmão e mama, e refletem o crescente impulso da linha de pr...

LOS ANGELES--(BUSINESS WIRE)--CCC Investors Have Opportunity to Join CCC Intelligent Solutions Holdings Inc. Fraud Investigation with SBS Law...

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors about a class action on behalf of purchasers of common stock of Papa John’s International, Inc. (NASDAQ: PZZA) between August 7, 2025 and August 5, 2026. Papa Johns describes itself as a “global chain pizza company that both operates and franchises restaurants in North America and various international markets.”For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-7...

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), società oncologica globale, oggi ha annunciato nuovi dati provenienti da vari farmaci sperimentali diversificati in tutte le sue aree terapeutiche prioritarie relative ai tumori solidi al Congresso 2026 dell'European Society for Medical Oncology (ESMO), che si svolge a Madrid dal 23 al 27 ottobre. Il testo originale del presente annuncio, redatto nella lingua di partenza, è la versione ufficiale c...